Liberty Energy Inc. Class A common stock vs Novartis AG — how do they compare? Liberty Energy Inc. Class A common stock trades at $19 (market cap $3.08B), while Novartis AG trades at $143.75 (market cap $268.57B). The key difference: Novartis AG is far larger — about 87.2× Liberty Energy Inc. Class A common stock's market cap, and Novartis AG pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold Liberty Energy Inc. Class A common stock for 1 Days and Novartis AG for 82 Days on average.
| LBRT | NVS | |
|---|---|---|
Market Cap | $3.08B | $268.57B |
Volume | 4,917,315 | 1,532,573 |
Sector | Energy | Health |
52-Week High | $33.93 | $168.62 |
52-Week Low | $11.94 | $121.80 |
Typical Hold Time | 1 Days | 82 Days |
Enterprise Value | $4.13B | $309.89B |
Dividend Yield | 1.91% | 3.31% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
NVS trades at $143.11, down 0.12% on the day, with a bearish technical signal and mixed earnings history including a recent Q1 2026 miss. The company maintains strong profitability with a 22.5% net income margin and 30.55% ROE, while recent news highlights a major $7.8B licensing deal with China's Abogen and ongoing investor scrutiny following clinical trial setbacks.
The outlook is cautious; analyst consensus is a Hold with a $146 price target, but risks include pipeline disappointments and M&A execution. Upside hinges on successful drug launches and deal integration, while downside stems from competitive pressures and regulatory challenges.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Liberty Energy provides completion services and technologies for onshore oil, natural gas, and geothermal producers in North America. It also offers distributed power and energy-storage solutions through Liberty Power Innovations.
Read more on LBRT →Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →